BURLINGTON, Mass., July 17, 2013 (GLOBE NEWSWIRE) -- Edison Investment Research has launched research coverage of LeMaitre Vascular, Inc. (Nasdaq:LMAT) under the direction of analyst Jason Zhang, PhD. Mr. Zhang joins research analysts at Barrington Research, Canaccord Genuity and Sidoti & Company in their coverage of LeMaitre.
About Edison Investment Research
Edison Investment Research provides research and support services to retained corporate and investor clients worldwide. Investor services include a team of research analysts who provide bespoke research and alpha generating investment ideas to fund managers worldwide. Corporate services include an Investor Access Service which actively markets companies to professional investors, and a Commercial Due Diligence Service which assists companies, private equity houses, and corporate finance teams in identifying and assessing potential corporate transactions.
About LeMaitre Vascular
LeMaitre Vascular is a provider of devices and implants for the treatment of peripheral vascular disease, a condition that affects more than 20 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. Additional information can be found at http://www.lemaitre.com.
LeMaitre and the LeMaitre Vascular logo are registered trademarks of LeMaitre Vascular, Inc.